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robust in the one-way sensibility analyses and the probabilistic sensitivity analy-
sis indicating that the absence of monitoring strategy has the highest probability 
of cost-effectiveness ConClusions: Long-run WBC monitoring based on current 
national detection guidelines is not cost-effective, even by unrealistically high 
agranulocytosis prevalence. New guidelines are needed to improve WBC monitor-
ing in schizophrenic patients receiving Clozapine.
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objeCtivos: evaluar los resultados clinicos y funcionales ( grado de satisfacción 
) de paciente con enfermedad de kienbock ttratados con osteotomia de acor-
tamiento radial. MetodologíAs: estudio realizado en la umae de traumato-
logia y ortopedia lomas verdes del imss, en el servicio de cirugia de mano, en 
un periodo comprendido entre 2000 al 2003, con seguimiento de 5 años.estudio 
retrospectivo, observacional, transversal. se estudiaron ´18 pacientes de ambos 
sexos con diagnostico de enfermedad de kienbock utilizando la clasificacion de 
litchman, evaluados con las escala de wrist mayo score y QDash. pba estadistica 
de wiscolson ResultAdos: se obtuviero 18 paciente 9 mujeres y 9 hombres, el 
84% obreros 16% al hogar, de acuerdo al resultados de la escla funcional wrist 
mayo score fueron 56% buenos, 33% excelentes, 5.5% malo, 5% regulares, con 25 
puntos de grado de satifaccion de acuerdo al QDash. un paciente fue reinterve-
nido 2 años posteriores al cual se le realizo una artrodesis delas cuatro esqui-
nas. ConClusiones: la evaluacion clinica y funcional, sugiere una eficacia 
aceptable de la osteotomia de acortamiento radial y provee datos alentadorespara 
continuar con este tipo de tratamiento.
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objeCtives: Recurrent bleeding among severe hemophilia A children can lead to 
disability and lower health-related quality of life (HRQOL). Little is known about 
how many bleeds can be endured before patients report an impact on health 
outcomes. The objective was to assess health outcomes of pediatric patients 
reporting a zero annual bleed rate (ABR) to identify the impact of higher ABRs on 
outcomes. Methods: This cross-sectional survey of parents of severe hemophilia 
A patients aged 2-17 was conducted in Argentina, Chile, Colombia, Mexico and 
Panama. Eligible, consenting patients completed a questionnaire: from October-
November 2009 (Argentina), June-August 2011 (Chile, Colombia, Mexico) and 
September-October 2012 (Panama). HRQOL was measured by the Pediatric Quality 
of Life Inventory (PedsQL). ABR, target joints and school days missed were also 
assessed. Results: A total of 211 parents of severe hemophilia A children com-
pleted the survey. Compared to patients with a 0 ABR who reported a mean PedsQL 
Total score of 76.6, patients with ABR categories of: 3-4, 5-10, 11-20, 21-30, 31-50, 51 
or more showed significantly worse mean PedsQL Total scores of: 66.4, 63.5, 67.4, 
62.5, 62.4 and 59.9 respectively (all p< 0.05). Similarly, compared to patients with 0 
ABR who reported a mean number of target joints of 0.69, patients with higher ABR 
categories showed significantly higher mean target joints: 1.49, 2.57, 3.42, 3.47, 3.74, 
4.67 (all p< .05). Differences in missed days from school showed the same significant 
trend when comparing 0 ABR to ABR categories of 3-4 and beyond. There were no 
significant differences between patients with zero compared to 1-2 ABR on these 
health outcomes. ConClusions: This analysis suggests that even 3-4 bleeds/year 
may have a negative impact on a patient’s joint health, missed school days and 
HRQOL. Efforts to maintain a 0 ABR among pediatric patients with severe hemophilia 
A may help ensure optimal outcomes.
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objeCtives: To evaluate the efficacy, safety and tolerability of 1 and 10 mg/kg beli-
mumab, a biologic drug, for the treatment of Systemic Lupus Erythematosus (SLE) 
through a meta-analysis, comparing these treatments with placebo. Methods: A 
systematic review and meta-analysis of randomized, placebo-controlled trials of beli-
mumab was conducted. Data were collected from several databases until August 2012. 
Efficacy outcomes included the SELENA-SLEDAI score (Safety of Estrogens in Lupus 
Erythematosus National Assessment version of the SLE Disease Activity Index), SRI 
(Systemic Lupus Erythematosus Responder Index), normalization of low C3 (< 90 mg/
kg), and anti-dsDNA positive to negative. Data on safety included any adverse events, 
serious adverse events, severe adverse events, death, malignancy, infections, and infu-
sion reactions. We also evaluated withdrawals from treatment due to lack of efficacy 
or adverse events. Results: Fours studies were included in this study. Anti-dsDNA 
positive to negative was the most significant efficacy outcome in our meta-analysis for 
both of the evaluated concentrations. No significant differences in the safety data were 
observed between the belimumab (1 and 10 mg/kg) and placebo groups. Tolerability 
results revealed no significant differences in withdrawals due to lack of efficacy 
and adverse events between the belimumab and placebo groups. ConClusions: 
Belimumab exhibited good efficacy results, especially at 10 mg/kg, a good safety profile, 
and adequate tolerability, which indicates that this biologic drug is a promising therapy 
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objeCtives: Data on the impact of asthma in Latin American countries is limited. 
The purpose of this study was to examine the association between partly- and 
uncontrolled asthma and asthma-related health care outcomes among patients 
residing in Argentina, Brazil, Mexico, Venezuela and the Common wealth of Puerto 
Rico. Methods: Adults and parents of adolescents (12-17 years) with physician 
diagnosed asthma and asthma medication use or asthma attacks in the past year 
were surveyed as part of the 2011 Latin America Asthma Insights and Management 
(AIM) survey. Using Global Initiative for Asthma (GINA) guidelines as a reference, 
respondents were categorized into three levels of asthma control: well-controlled, 
partly- controlled, and uncontrolled. Chi-square tests and adjusted logistic regres-
sion were used to determine odds ratios (ORs) to assess the relation of degree of 
asthma control with utilization of asthma medications, health care outcomes, and 
productivity. Results: Data was available for 2169 completed surveys. Overall, 
7% of the patients surveyed had asthma that was classified as well-controlled, 
with the highest proportion in Mexico (9.4%) and the lowest in Venezuela (3.0%). 
Patients whose asthma was not well-controlled were significantly more likely to 
report use of asthma medications (ORs ranging from 1.5-42) and to have had emer-
gency health care visits or hospitalizations for their asthma in the previous year 
(ORs ranging from 2.1-5.9). Respondents with uncontrolled asthma also reported 
significant decreases in productivity due to asthma compared to patients with 
well-controlled asthma. ConClusions: Patients who did not have well-controlled 
asthma had greater utilization rates of asthma medications and emergency health 
care services compared to patients whose asthma was well-controlled. These asso-
ciations strongly suggest that emphasis on improving asthma control could have 
substantial effects on patient productivity and utilization of health care resources.
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objeCtivos: Determinar las variables socioeconómicas asociadas a pacientes con 
enfermedad vascular cerebral (EVC) y antecedentes de tabaquismo, tratados en 
un centro neurológico de tercer nivel en México. MetodologíAs: Es un estudio 
cuantitativo, descriptivo, transversal y retrospectivo. Los pacientes debían tener 
edades ≥ 35 años, antecedentes de tabaquismo y diagnóstico de EVC; clasificados 
por el sistema CIE-10 (I60-I69). Se revisaron 174 expedientes del 2011. Se utilizó el 
análisis de componentes principales para estimar los pesos de las variables socioec-
onómicas. La adecuación del modelo se realizó mediante la medida de Kaiser-Meyer-
Oklin (KMO), la prueba de Bartlett y la consistencia interna mediante el alpha de 
Crombach (α ). ResultAdos: De los 174 pacientes 78(45%) presentaron antecedentes 
de tabaquismo y de estos 49(63%) fueron hombres, con 58±14 (media, DE) años de 
edad y 9.4±5.3 de escolaridad, nivel socioeconómico de 2.3±1.1, 71(91%) habita en 
departamentos populares y 37(47%) se dedicaron al hogar o fueron trabajadores no 
calificados. Se obtuvo un α = 0.80, KMO= 0.78 y Bartlett (p= 0.000). Dos componentes 
explicaron 58.3% de la varianza total. El primero; (42.02%), se integró por las vari-
ables servicio intra-domiciliario (Ponderación;0.763), estatus socioeconómico (0.749), 
escolaridad (0.748), zona de ubicación (0.673), material de construcción (0.707), ubi-
cación de la vivienda (0.673) y ocupación (0.437). el segundo; (16.24%), con el tipo de 
vivienda (0.564) y número de habitaciones (0.460). ConClusiones: Los pacientes 
atendidos por EVC se caracterizaron por niveles bajos de escolaridad y clasificación 
socioeconómica, ocupaciones poco remunerables y edad avanzada; que los hace 
vulnerables a la enfermedad.
SYStemic DiSOrDerS/cOnDitiOnS – clinical Outcomes Studies
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objeCtives: White Blood Cell (WBC) monitoring in schizophrenic patients treated 
by Clozapine aims to prevent agranulocytosis. We assess the cost-effectiveness of 
WBC monitoring strategies based on three national regulations and an additional 
weekly short-run monitoring compared to the absence of monitoring. Methods: 
A decision analytic model was built to perform a cost-utility analysis comparing 
distinct monitoring strategies from a health care perspective with a 3-year time 
horizon. Clinical and resources used parameters were based on national Clozapine 
patients’ registries, cohorts, and pharmacovigilance data; health-related quality 
of life and mortality estimates were derived from literature reviews. Robustness 
of results was challenged with one-way and probabilistic sensitivity analy-
ses. Results: Compared to the absence of monitoring, the number needed to treat 
of all strategies to avoid one death was 5,000. The gains in survival time adjusted 
on quality of life were less than 1 day, resulting in prohibitive incremental cost-
effectiveness ratios (ICER) of at least 1 million USD per QALY gained,. The ICER 
increased with higher frequency and longer monitoring duration. The results remain 
